Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebelimab + Chemotherapy and Apatinib Maintenance in ES-SCLC
NCT06614621Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Feb 2025
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in small cell lung cancer (SCLC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Progression-Free Survival at 12 months. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06614621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06614621.